Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
astrazeneca
7
×
biotech
7
×
life sciences
national blog main
san francisco blog main
7
×
san francisco top stories
startups
7
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
cancer immunotherapy
deals
pfizer
abbvie
alzheimer's disease
cancer
clinical trials
europe blog main
europe top stories
gilead sciences
What
bio
roundup
drug
acquisitions
amid
bombast
cancer
caught
ceo
coronavirus
daniel
debate
develop
discussion
efforts
gilead
meso’s
miss
o’day
pandemic
pfizer’s
presidential
promise
response
sciences
tuesday’s
vaccine
viewers
week
alzheimer’s
announced
annual
approved
assessed
attention
available
biggest
biological
biologics
biotech
Language
unset
Current search:
astrazeneca
×
biotech
×
" san francisco blog main "
×
startups
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More